Artificial Intelligence: AI Could Simulate 40,000 Hypothetical Bioweapons In A Mere Six Hours

https://dailyalts.com/wp-content/uploads/2022/03/weapons-gc0c7afad9_640.jpg

Researchers ran a test to gauge AI’s potential to do harm.

A team of researchers from Collaborations Pharmaceuticals Inc received an invitation to an international security conference that reviews developments in chemistry, biology and enabling technologies that may have implications for chemical and bioweapons. Their brief: To play devil’s advocate to the impression that AI technology for drug discovery could only be used benevolently. Their finding: AI designed 40,000 molecules that had toxic and chemical warfare implications in just six hours. (Nature.com)

Bioweapons: Surprise finding

“In developing our presentation to the Spiez meeting, we opted to explore how AI could be used to design toxic molecules,” say Fabio Urbina, Filippa Lentzos, Cédric Invernizzi & Sean Ekins in their article in Nature. “It was a thought exercise we had not considered before that ultimately evolved into a computational proof of concept for making biochemical weapons.”

The researchers inverted the instructions to MegaSyn, their de novo molecule generator that used machine learning for drug discovery for the cure of human diseases.

“This generative model normally penalizes predicted toxicity and rewards predicted target activity,” writes the team. “We simply proposed to invert this logic by using the same approach to design molecules de novo, but now guiding the model to reward both toxicity and bioactivity instead.”

The model generated 40,000 hypothetical molecules, including VX, one of the most toxic chemical warfare agents developed during the twentieth century, in less than six hours.

The researchers found that the model designed many new molecules that were potentially more toxic than publicly known chemical warfare agents.

“By inverting the use of our machine learning models, we had transformed our innocuous generative model from a helpful tool of medicine to a generator of likely deadly molecules,” the team writes.

“Our proof of concept thus highlights how a nonhuman autonomous creator of a deadly chemical weapon is entirely feasible.”

Related Story: “AI Will Never Be Ethical,” Says An AI Tool In A Debate

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Shape

Latest Alternative Investment News

https://dailyalts.com/wp-content/uploads/2023/12/AMD_headquarters_santa_clara.624da707519a6.jpg
Artificial Intelligence: AMD Takes On Rivals In The AI Chip Sweepstakes
December 7, 2023     Artificial Intelligence, News

Chipmaker AMD (NASDAQ: AMD) has unveiled a range of innovative AI solutions spanning from data centers to personal computers. The AMD Instinct MI300 Series features data center AI accelerators, while…

https://dailyalts.com/wp-content/uploads/2023/12/RHCEU-Inline.jpg
Digital Assets: Robinhood Debuts Crypto Trading On Its App In The EU
December 7, 2023     Digital Assets, FinTech, News

Robinhood (NASDAQ: HOOD) has launched its Crypto app in the European Union (EU), allowing eligible customers to engage in crypto trading with the added incentive of earning Bitcoin rewards. Customers…

https://dailyalts.com/wp-content/uploads/2023/12/Samsung_UK_Samsung_Pay_Lifestyle_0552-revised-Pictogram-23.11.30-1024x744-1.png
FinTech: Samsung Electronics Ties With Mastercard’s Wallet Express
December 7, 2023     FinTech, News

Samsung Electronics (KRX: 005930) and Mastercard (NYSE: MA) have partnered to launch the Wallet Express program, offering banks and card issuers a cost-effective way to expand digital wallet offerings. Through…

https://dailyalts.com/wp-content/uploads/2023/12/Revaia-founders.jpg
Venture Capital: Revaia, Europe’s Biggest Female-Led VC Firm, Racks Up $160M For Second Fund
December 7, 2023     ESG and Sustainability, News, Venture Capital

Revaia, Europe’s largest female-founded venture capital firm, has successfully raised €150 million ($160 million) for its second fund, Revaia Growth II. The funding was secured from sovereign wealth funds, family…